Search

Your search keyword '"Frohneberg D"' showing total 338 results
Start Over Author "Frohneberg D"
338 results on '"Frohneberg D"'

3. Anaphylaxis

Author

Bader, P., Frohneberg, D., Hohenfellner, Markus, editor, and Santucci, Richard A., editor

Published
2007
Full Text
View/download PDF

13. Führt die Laparoskopie beim Prostatakarzinom zu neuen Metastasierungsmustern?

Author

Bodenbach, M, Bader, P, Frohneberg, D, and Teber, D

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Peritoneale Metastasen eines Prostatakarzinoms nach radikaler Prostatektomie sind eine Rarität. Der erste Fallbericht nach laparoskopischer Prostatektomie datiert aus dem Jahr 2011, die erste Veröffentlichung nach roboter-assistierter Operation aus dem Jahr 2012. Seither sind vereinzelte Veröffentlichungen[zum vollständigen Text gelangen Sie über die oben angegebene URL], 60. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V.

Published
2019
Full Text
View/download PDF

16. Spermatozytischer Tumor – eine neue Tumorentität des Hodens?

Author

Engels, CL, Bader, P, and Frohneberg, D

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Die Klassifikation der Hodentumore beschrieb bis 2015 ein spermatozytisches Seminom. Im Konsens der an dieser Einteilung mitwirkenden Pathologen und Urologen wurde dieser Tumor ausgegliedert, da er eine eigene Tumorentität darstellt. Bekannt ist das – wenn auch eher seltene spermatozytische[zum vollständigen Text gelangen Sie über die oben angegebene URL], 59. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V. - Urologie im Südwesten: Innovation aus Tradition

Published
2018
Full Text
View/download PDF

17. Harnröhrenpolyp mit Leistenschwellung – Differentialdiagnose Urethrakarzinom

Author

Daagi, V, Bader, P, and Frohneberg, D

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Das Urethrakarzinom der Frau ist eine Rarität. Daher sind die Therapieempfehlungen auch nur von einem geringen Evidenzgrad. Der Metastasierungsweg entspricht dem des Mannes mit Penis- oder Urethrakarzinom. Wir möchten anhand des obigen Fallbeispiels die diagnostischen und therapeutischen Pfade[zum vollständigen Text gelangen Sie über die oben angegebene URL], 59. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V. - Urologie im Südwesten: Innovation aus Tradition

Published
2018
Full Text
View/download PDF

21. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer

Author

Joniau, S, Spahn, M, Briganti, A, Gandaglia, G, Tombal, B, Tosco, L, Marchioro, G, Hsu, Cy, Walz, J, Kneitz, B, Bader, P, Frohneberg, D, Tizzani, A, Graefen, M, van Cangh, P, Karnes, Rj, Montorsi, F, van Poppel, H, Gontero, Paolo, European Multicenter Prostate Cancer Clinical, Translational Research Group, Joniau, S, Spahn, M, Briganti, A, Gandaglia, G, Tombal, B, Tosco, L, Marchioro, G, Hsu, Cy, Walz, J, Kneitz, B, Bader, P, Frohneberg, D, Tizzani, A, Graefen, M, van Cangh, P, Karnes, Rj, Montorsi, Francesco, van Poppel, H, and Gontero, P.

Subjects
Oncology, Male, Biopsy, Physics::Medical Physics, Predictive Value of Test, urologic and male genital diseases, Prostate cancer, Locally advanced prostate cancer, Decision Support Technique, Retrospective Studie, Risk Factors, Pretreatment table, 610 Medicine & health, Pathologic stage, Lymph Node, Kallikrein, Radical prostatectomy, Europe, Treatment Outcome, Lymphatic Metastasis, Kallikreins, Human, medicine.medical_specialty, Logistic Model, Quantitative Biology::Tissues and Organs, Urology, Locally advanced, Reproducibility of Result, Decision Support Techniques, Predictive Value of Tests, Internal medicine, medicine, Humans, Neoplasm Staging, Retrospective Studies, Prostatectomy, business.industry, Risk Factor, Patient Selection, Prostatic Neoplasms, Reproducibility of Results, Lymphatic Metastasi, Prostate-Specific Antigen, medicine.disease, Logistic Models, Computer Science::Computer Vision and Pattern Recognition, Prostatic Neoplasm, Lymph Node Excision, Lymph Nodes, Neoplasm Grading, business
Abstract

Background Pretreatment tables for the prediction of pathologic stage have been published and validated for localized prostate cancer (PCa). No such tables are available for locally advanced (cT3a) PCa. Objective To construct tables predicting pathologic outcome after radical prostatectomy (RP) for patients with cT3a PCa with the aim to help guide treatment decisions in clinical practice. Design, setting, and participants This was a multicenter retrospective cohort study including 759 consecutive patients with cT3a PCa treated with RP between 1987 and 2010. Intervention Retropubic RP and pelvic lymphadenectomy. Outcome measurements and statistical analysis Patients were divided into pretreatment prostate-specific antigen (PSA) and biopsy Gleason score (GS) subgroups. These parameters were used to construct tables predicting pathologic outcome and the presence of positive lymph nodes (LNs) after RP for cT3a PCa using ordinal logistic regression. Results and limitations In the model predicting pathologic outcome, the main effects of biopsy GS and pretreatment PSA were significant. A higher GS and/or higher PSA level was associated with a more unfavorable pathologic outcome. The validation procedure, using a repeated split-sample method, showed good predictive ability. Regression analysis also showed an increasing probability of positive LNs with increasing PSA levels and/or higher GS. Limitations of the study are the retrospective design and the long study period. Conclusions These novel tables predict pathologic stage after RP for patients with cT3a PCa based on pretreatment PSA level and biopsy GS. They can be used to guide decision making in men with locally advanced PCa. Patient summary Our study might provide physicians with a useful tool to predict pathologic stage in locally advanced prostate cancer that might help select patients who may need multimodal treatment.

Published
2015

22. Transsacral Block

Author

Gerbershagen, H. U., Frohneberg, D. H., Panhans, C., Waisbrod, H., Van Kleef, Jack W., editor, Burm, Anton G. L., editor, and Spierdijk, Johan, editor

Published
1984
Full Text
View/download PDF

24. Supravesikale Harnableitung

Author

Albert, L., Rodeck, G., Beyer, G., Ziegler, G., Schreiter, F., Frohneberg, D., Egghart, G., Miller, K., Hautmann, R., Spehr, Ch., Melchior, H., Knop, I., Studer, U. E., Wüthrich, Ch., Ackermann, D., Zingg, E. J., and Ackermann, Rolf, editor

Published
1988
Full Text
View/download PDF

25. Postersitzung 3: Der metastasierte Hodentumor — Probleme der Palliativtherapie urologischer Tumoren

Author

Derouet, H., Braedel, H. U., Ziegler, M., Zwergel, Th., Khorsandian, Ch., Jaeger, N., Dewes, W., Dieckmann, K.-P., von Keyserlingk, H., Kratzik, Ch., Kuzmits, R., Aiginger, P., Schwarz, H. P., Kuber, W., Mayr, W. R., Ringert, R.-H., Meyer-Schwickerath, M., Bergner, S., Behrendt, H., Becker, T., Bauer, H. W., van Ahlen, H., Probst, E., Boldt, I., von Stauffenberg, A., Vahlensieck, W., Schaefer, M., Brühl, P., Studer, U. E., Böhle, A., Sonntag, R. W., Kraft, R., Havers, W., Stollmann, B., Kröpfl, D., Jung, P., Becht, E., Mast, G. J., Thon, W. F., Sparwasser, C., Gilbert, P., Ulshöfer, B., Pflüger, K.-H., Mack, J., von Keitz, A., Rodeck, G., Kazoń, M., Egghart, G., Hautmann, R., Frohneberg, D., Bachor, R., Egghart, H. G., Hautmann, R. E., Schilling, A., Friesen, A., Schmid, G., Voigt, A., Jellinghaus, W., and Ackermann, Rolf, editor

Published
1988
Full Text
View/download PDF

26. Postersitzung 2: Das metastasierte Prostatakarzinom

Author

die urologische Arbeitsgruppe Süd-Ost Niederlande, Seitz, G., Kolles, H., Niemeyer, A.-H., Wernert, N., Dhom, G., Allhoff, E., Franzen, W., Engelking, R., Csapo, Z., Weißmüller, J., Sigel, A., Oremek, G., Seiffert, U. B., Siede, W. H., Kirsten, R., Heinert, G., Breul, J., Kreuzfelder, E., Behrendt, J., Kirchheimer, J. C., Christ, G., Pflüger, H., Binder, B. R., Helpap, B., Abadi, H.-Al, Nagel, R., Wallenberg Pachaly, H. V., Gatto, M., Fernandez del Moral, P., Hoefakker, J. W., Debruyne, F. M. J., Kramer, W., Sandow, J., Althoff, P.-H., Balducci, M., Jonas, D., Bergner, S., Ringert, R. H., Rössler, W., Wieland, W., Tischer, F., Peters, H.-P., Wirth, M., Grups, J., Heckl, W., Frohmüller, H., Walther, R., Schrott, K. M., Petrow, V., Frankenschmidt, A., Sommerkamp, H., Wenderoth, U. K., Frohneberg, D., Elsäßer, E., Hautmann, R., Elsäßer, A., Jacobi, G. H., and Ackermann, Rolf, editor

Published
1988
Full Text
View/download PDF

30. Radikale Zystektomie bei cT4 'very-high risk' Prostatakarzinom: Eine multizentrische Outcome Studie von 62 Patienten

Author

Spahn, M., Joniau, S., Briganti, A., Gontero, P., Kneitz, B., Frohneberg, D., Van Poppel, H., and Karnes, J.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Prostatakarzinompatienten mit einem T4 Tumor haben ein hohes Rezidiv- und Sterblichkeitsrisiko. Die optimale Behandlung dieser Patienten wird kontrovers diskutiert. In der kürzeren Vergangenheit hat die operative Behandlung dieser Tumoren im Rahmen eines multimodalen Therapiekonzepts[for full text, please go to the a.m. URL], 61. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

Published
2015
Full Text
View/download PDF

31. Stratification of high-risk prostate cancer into prognostic categories: A european multi-institutional study

Author

Joniau, S, Briganti, A, Gontero, Paolo, Gandaglia, G, Tosco, L, Fieuws, S, Tombal, B, Marchioro, G, Walz, J, Kneitz, B, Bader, P, Frohneberg, D, Tizzani, A, Graefen, M, van Cangh, P, Karnes, Rj, Montorsi, F, Van Poppel, H, Spahn, M, European Multicenter Prostate Cancer Clinical, Translational Research Group, Joniau, Steven, Briganti, Alberto, Gontero, Paolo, Gandaglia, Giorgio, Tosco, Lorenzo, Fieuws, Steffen, Tombal, Bertrand, Marchioro, Giansilvio, Walz, Jochen, Kneitz, Burkhard, Bader, Pia, Frohneberg, Detlef, Tizzani, Alessandro, Graefen, Marku, van Cangh, Paul, Karnes R., Jeffrey, Montorsi, Francesco, Van Poppel, Hein, and Spahn, Martin

Subjects
Oncology, High-risk prostate cancer, Male, medicine.medical_specialty, Urology, Predictive Value of Test, Disease, Risk Assessment, Stratification (mathematics), Disease-Free Survival, Prostate cancer, Locally advanced prostate cancer, Risk groups, Predictive Value of Tests, Risk Factors, Retrospective Studie, Internal medicine, medicine, Humans, Risk stratification, Proportional Hazards Models, Retrospective Studies, Aged, Neoplasm Staging, business.industry, Risk Factor, Risk group, Prostatic Neoplasms, Middle Aged, Prostate-Specific Antigen, medicine.disease, Europe, Survival Rate, Area Under Curve, Prostatic Neoplasm, Proportional Hazards Model, Neoplasm Grading, business, Human
Abstract

Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage ( 20 ng/ml). The first "extended" model includes all seven possible combinations; the second "simplified" model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA > 20 ng/ml and stage cT3-4); and a poor prognosis subgroup (GS 8-10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R: 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively (p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.

Published
2015

32. 100 Jahre Urologie – Operative Techniken

Author

R. Hohenfellner, Popken G, M. Marberger, Frohneberg D, Engelmann U, Michael C. Truss, Rainer Hofmann, J. U Stolzenburg, Margit Fisch, and Dieter Jocham

Subjects
medicine.medical_specialty, business.industry, Urology, General surgery, medicine, business
Published
2006

35. The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis

Author

Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schröder F, van Cangh P, van Poppel H, Spahn M., BRIGANTI , ALBERTO, Schubert, M, Joniau, S, Gontero, P, Kneitz, S, Scholz, Cj, Kneitz, B, Briganti, Alberto, Karnes, Rj, Tombal, B, Walz, J, Hsu, Cy, Marchioro, G, Bader, P, Bangma, C, Frohneberg, D, Graefen, M, Schröder, F, van Cangh, P, van Poppel, H, and Spahn, M.

Subjects
ddc:617, Article Subject, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, Research Article
Abstract

Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n = 86) or no adjuvant ADT (group 2, n = 86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5-10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.

Published
2012

36. THE IMPACT OF AGE AND COMORBIDITIES ON SURVIVAL AFTER RADICAL PROSTATECTOMY IN HIGH-RISK PROSTATE CANCER PATIENTS: A COMPETING-RISKS ANALYSIS

Author

BRIGANTI , ALBERTO, Joniau S, Spahn M, Karnes J, Bianchi M, Sun M, Kneitz B, Frohneberg D, Bader P, Marchioro G, Terrone C, MONTORSI, FRANCESCO, Van Poppel H, Gontero P., Briganti, Alberto, Joniau, S, Spahn, M, Karnes, J, Bianchi, M, Sun, M, Kneitz, B, Frohneberg, D, Bader, P, Marchioro, G, Terrone, C, Montorsi, Francesco, Van Poppel, H, and Gontero, P.

Published
2012

40. THREE OR MORE POSITIVE NODES AT RADICAL PROSTATECTOMY REPRESENT A SIGNIFICANT CUT-OFF VALUE FOR CSS IN HIGH-RISK PROSTATE CANCER, WHILE 1 OR 2 POSITIVE NODES DO NOT INFLUENCE CSS

Author

Joniau J, Van Baelen A, Gontero P, Marchioro G, Capitanio U, Tombal B, Hsu CY, Akdogan B, Bader P, Frea B, Frohneberg D, Kneitz B, Riedmiller H, Tizzani A, Van Poppel H, Spahn M., BRIGANTI , ALBERTO, Joniau, J, Van Baelen, A, Gontero, P, Briganti, Alberto, Marchioro, G, Capitanio, U, Tombal, B, Hsu, Cy, Akdogan, B, Bader, P, Frea, B, Frohneberg, D, Kneitz, B, Riedmiller, H, Tizzani, A, Van Poppel, H, and Spahn, M.

Published
2011

41. THE NUMBER OF POSITIVE SECTION MARGINS IN HIGH-RISK PROSTATE CANCER IS A POWERFUL AND INDEPENDENT PREDICTOR OF CANCER-SPECIFIC AND OVERALL SURVIVAL IN HIGH-RISK LOCALIZED PROSTATE CANCER

Author

Joniau S, Gontero P, Marchioro G, Capitanio U, Tombal B, Hsu CY, Akdogan B, Bader P, Frea B, Frohneberg D, Kneitz B, Riedmiller H, Tizzani A, Van Poppel H, Spahn M., BRIGANTI , ALBERTO, Joniau, S, Gontero, P, Briganti, Alberto, Marchioro, G, Capitanio, U, Tombal, B, Hsu, Cy, Akdogan, B, Bader, P, Frea, B, Frohneberg, D, Kneitz, B, Riedmiller, H, Tizzani, A, Van Poppel, H, and Spahn, M.

Published
2011

43. TIME TO BIOCHEMICAL RECURRENCE IS A STRONG AND INDEPENDENT PREDICTOR OF CSS AND OS IN HIGH-RISK PROSTATE CANCER

Author

Spahn M, Joniau S, Marchioro G, Tombal B, Walz J, Hsu C. Y, Bader P, Frohneberg D, Graefen M, Tizzani A, Van Cangh P, MONTORSI, FRANCESCO, Van Poppel H, Gontero P., BRIGANTI , ALBERTO, Spahn, M, Gontero, P, Briganti, Alberto, Marchioro, G, Tombal, B, Walz, J, Hsu, Cy, Bader, P, Frohneberg, D, Graefen, M, Tizzani, A, Van Cangh, P, Montorsi, Francesco, Van Poppel, H, Joniau, S., Joniau, S, Hsu C., Y, and Gontero, P.

Published
2011

44. IN HIGH-RISK PROSTATE CANCER, THE NUMBER OF LYMPH NODES REMOVED AT RADICAL PROSTATECTOMY DOES NOT AFFECT THE RISK OF CANCER RELATED DEATH OR DEATH FROM ANY CAUSE

Author

Joniau S, Van Baelen A, Spahn M, Marchioro G, Capitanio U, Tombal B, Hsu CY, Akdogan B, Bader P, Frea B, Frohneberg D, Kneitz B, Riedmiller H, Tizzani A, Van Poppel H, Gontero P., BRIGANTI , ALBERTO, Joniau, S, Van Baelen, A, Spahn, M, Briganti, Alberto, Marchioro, G, Capitanio, U, Tombal, B, Hsu, Cy, Akdogan, B, Bader, P, Frea, B, Frohneberg, D, Kneitz, B, Riedmiller, H, Tizzani, A, Van Poppel, H, and Gontero, P.

Published
2011

45. CUMULATIVE NUMBER OF HIGH-RISK FACTORS IS HIGHLY PREDICTIVE OF CANCER-RELATED OUTCOMES AND OVERALL SURVIVAL IN PATIENTS WITH HIGH-RISK LOCALIZED PROSTATE CANCER

Author

Joniau S, Gontero P, Tombal B, Marchioro G, Walz J, Vander Eeckt K, Hsu CY, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, Van Cangh P, MONTORSI, FRANCESCO, Van Poppel H, Spahn M., BRIGANTI , ALBERTO, Joniau, S, Gontero, P, Briganti, Alberto, Tombal, B, Marchioro, G, Walz, J, Vander Eeckt, K, Hsu, Cy, Kneitz, B, Bader, P, Frohneberg, D, Tizzani, A, Graefen, M, Van Cangh, P, Montorsi, Francesco, Van Poppel, H, and Spahn, M.

Published
2010

46. HIGH-RISK PROSTATE CANCER PATIENTS WHO HAVE SPECIMEN-CONFINED DISEASE AT PATHOLOGY HAVE EXCEPTIONALLY GOOD OUTCOMES AFTER SURGERY

Author

Gontero P, Spahn M, Marchioro G, Tombal B, Walz J, Bader P, Frohneberg D, Graefen M, Tizzani A, Van Cangh P, MONTORSI, FRANCESCO, Van Poppel H, Joniau S., BRIGANTI , ALBERTO, Gontero, P, Spahn, M, Briganti, Alberto, Marchioro, G, Tombal, B, Walz, J, Bader, P, Frohneberg, D, Graefen, M, Tizzani, A, Van Cangh, P, Montorsi, Francesco, Van Poppel, H, and Joniau, S.

Published
2010

47. VALUE OF EXTENDED LYMPH NODE DISSECTION IN NODE POSITIVE HIGH-RISK LOCALIZED PROSTATE CANCER IS UNCERTAIN

Author

Joniau S, Gontero P, Marchioro G, Akdogan B, Hsu CY, Vander Eeckt K, Bader P, Kneitz B, Walz J, Frohneberg D, Graefen M, MONTORSI, FRANCESCO, Tizzani A, Tombal B, Van Cangh P, Van Poppel H, Spahn M., BRIGANTI , ALBERTO, Joniau, S, Gontero, P, Briganti, Alberto, Marchioro, G, Akdogan, B, Hsu, Cy, Vander Eeckt, K, Bader, P, Kneitz, B, Walz, J, Frohneberg, D, Graefen, M, Montorsi, Francesco, Tizzani, A, Tombal, B, Van Cangh, P, Van Poppel, H, and Spahn, M.

Published
2010

48. Predicting favourable pathological outcome in patients with clinical high risk prostate cancer. A novel nomogram based on a multi-institutional analysis

Author

BRIGANTI , ALBERTO, Gallina A, Suardi N, Capitanio U, Colombo R, SALONIA, ANDREA, Guazzoni G, MONTORSI, FRANCESCO, Rigatti P, Spahn M, Joniau S, Gontero P, Marchioro G, Tombal B, Frohneberg D, Isbarn H, Bangma CH, Schroder FH, Kneitz B, Graefen M, Tizzani A, Van Poppel H., Briganti, Alberto, Gallina, A, Suardi, N, Capitanio, U, Colombo, R, Salonia, Andrea, Guazzoni, G, Montorsi, Francesco, Rigatti, P, Spahn, M, Joniau, S, Gontero, P, Marchioro, G, Tombal, B, Frohneberg, D, Isbarn, H, Bangma, Ch, Schroder, Fh, Kneitz, B, Graefen, M, Tizzani, A, and Van Poppel, H.

Published
2010

49. VALUE OF ELND IN LYMPH NODE NEGATIVE PATIENTS WITH HIGH-RISK LOCALIZED PROSTATE CANCER

Author

Joniau S, Gontero P, Giansilvio Marchioro G, Tombal B, Walz J, Akdogan B, Hsu C. Y, Bader P, Frohneberg D, Graefen M, Kneitz B, Tizzani A, Van Cangh P, MONTORSI, FRANCESCO, Van Poppel H, Spahn M., BRIGANTI , ALBERTO, Joniau, S, Gontero, P, Briganti, Alberto, Giansilvio Marchioro, G, Tombal, B, Walz, J, Akdogan, B, Hsu C., Y, Bader, P, Frohneberg, D, Graefen, M, Kneitz, B, Tizzani, A, Van Cangh, P, Montorsi, Francesco, Van Poppel, H, and Spahn, M.

Published
2010

50. IS SURGERY FOR HIGH-RISK LOCALIZED PROSTATE CANCER VALID IN THE ELDERLY POPULATION? AN ANALYSIS OF THE INFLUENCE OF AGE AN CANCER-SPECIFIC AND OVERALL SURVIVAL

Author

Gontero P, Spann M, Marchioro G, Tombal B, Hsu CY, Eeckt Vander K, Bader P, Walz J, Frohneberg D, Graefen M, MONTORSI, FRANCESCO, Tizzani A, Van Cangh A, Van Poppel H, Joniau S., BRIGANTI , ALBERTO, Gontero, P, Spann, M, Briganti, Alberto, Marchioro, G, Tombal, B, Hsu, Cy, Eeckt Vander, K, Bader, P, Walz, J, Frohneberg, D, Graefen, M, Montorsi, Francesco, Tizzani, A, Van Cangh, A, Van Poppel, H, and Joniau, S.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results